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Background: Exhausted T cells and regulatory T cells (Tregs) comprise diverse
subsets of tumor immunosuppressive microenvironment that play key roles in
tumor progress. Understanding subset diversity in T cells is a critical question
for developing cancer immunotherapy.
Methods:A total of 235 specimens from surgical resections of hepatocellular car-
cinoma (HCC) patientswere examined for infiltration of exhausted T cell (Tex) in
tumor and adjacent tissue. We conducted deep single-cell targeted immune pro-
filing onCD3+ cells collected from tumor tissues, adjacent normal tissues (ANTs)
and peripheral blood of HCC patients. Total 10 cell clusters were identified with
distinct distributions and characteristics.
Results:We observed transitional differentiation of exhausted CD8+T cells and
Tregs increasingly enriched in tumor tissue. The accumulation and location of
Tex were related to the differences in the long-term clinical outcome of HCC.
Furthermore, data of single-cell RNA-seq showed that (1) cells transforming from
effector CD8+ T cells to exhausted CD8+ T cells simultaneously expressed upreg-
ulated effector molecules and inhibitory receptors, (2) indicated alteration of
gene expression related to stress response and cell cycle at early exhaustion stage,
and (3) immunosuppressive Treg had profound activation in comparison to rest-
ing Tregs.
Conclusions:T cell exhaustion is a progressive process, and the gene-expression
profiling displayed T cell exhaustion and anergy are different. Accordingly, it
is possible that functional exhaustion is caused by the combination effects of
passive defects and overactivation in stress response. The results help to under-
stand the dynamic framework of T cells function in cancer which is important
for designing rational cancer immunotherapies.
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1 INTRODUCTION
Hepatocellular carcinoma (HCC), which accounts for 85%
to 90% of the pathological types of primary liver cancer,
has been rising globally in the past years, and now it is
the fifth common malignant tumor that ranks the third
leading cause of cancer-related mortality evaluated by the
World Health Organization (https://www.who.int/).1 It is
expected that it will continually to increase in some coun-
tries including the United States until 2030.2
In recent years, immune checkpoint inhibitors, such
as PD-1 and CTLA-4 inhibitors, have been indicated as
promising treatments for patients with cancers.3-5 These
“checkpoint blockade” therapeutics are aimed at improv-
ing tumor infiltrating T cells (TIL) activity by alleviat-
ing the regulatory mechanisms.6 Some antibodies, such
as nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), and
ipilimumab (anti-CTLA-4), have been approved by the
US FDA and have shown excellent therapeutic effect on
melanoma, nonsmall cell lung cancer, glioblastoma, large
B-cell lymphoma,multiplemyeloma, renal cell carcinoma,
and so on.7-10 Interestingly, when patients with advanced
HCC, immune checkpoint inhibitors also provide benefi-
cial results.4,11-13 Although checkpoint blockade, such as
PD-1 inhibitors can improve clinical outcomes, the effi-
cacy is variable between tumors or patients.14,15 In clini-
cal practice of the treatment of HCC, the immunotherapy
is represented by PD-1 or PD-L1; CTLA-4 antibodies had a
low disease remission rate.16-18 The reason is that in addi-
tion to the formation mechanism of the immune tolerance
microenvironment of liver cancer is complex, other fac-
tors related to chronic liver disease may also affect liver-
specific immune cells and the patient’s response to this
immunotherapy.19-21
One of possibilities to explain the variation could be due
to the major barriers of tumor therapies from exhausted
T cells and regulatory T cells (Tregs),22,23 which have dis-
played a dramatically altered pattern of differentiation.24,25
Therefore, it is essential to comprehend that T cell immune
community, which tightly links to tumor immunotherapy
response, in order to provide improved strategies to coor-
dinate the immune response system to eradicate cancer.
According to current knowledge and controversial/ incon-
sistent results, we set out a novel study using single-cell
transcriptome analysis from CD3+ cells to investigate cell
transition or differentiation leading to terminal exhaustion
or the accumulation of Tregs in HCC in a highly complex
tumor biological context.
This approach revealed the progressive process of TIL
differentiation and biology in HCC. First, the expression
of various cell-surface inhibitory receptors was elevated
in Tex. Second, the transcription level of genes encoding
molecules involved in stress response was downregulated
and possibly weakened the efficiency of these pathways.
Third, multiple genes related to cell cycle and growth fac-
tors were altered in the early exhausted CD8+ T cells.
Fourth, a striking changed differentiation pattern was
found in suppressive Treg cells, compared to resting Tregs,
including unique expression patterns of transcription fac-
tors, cytokines and interleukins. It is suggested potential
new targets of therapies inHCCby the defections and alter-




This study enrolled 248 patients with pathological diagno-
sis of HCC. Before the tumors were resected, all patients
did not undergo chemotherapy or radiation therapy. Paired
HCC tumors, ANTs, or peripheral blood were collected
from patients. ANTs were more than or equal to 3cm
away from the matched tumor tissues. Fresh specimens
from 13 HCC patients were obtained for the subsequent
CD3+ cell sorting, then single-cell RNA sequencing anal-
ysis or in vitro testing. Ethics committee’ approval was
obtained fromZhongshanHospital, FudanUniversity, and
written informed consent was obtained from all HCC
patients.
2.2 Sample preparation
Ficoll solution (17544202 GE healthcare) was used to
extract peripheral blood mononuclear cells (PBMCs) in
accordance with the manufacturer’s protocol. In short,
10 mL of fresh peripheral blood was harvested in an anti-
coagulation tube before surgery. The peripheral blood was
diluted with PBS at 1:1 dilution and gently transferred to a
centrifuge tube with Ficoll. PBMCs were isolated by frac-
tionation over Ficoll gradients, and then washed twice
with 1 × PBS.
Fresh tumor and ANT specimens were soaked in
RPMI-1640 medium (Gibco) with 10% FBS, then cut,
triturated, and passed through 40 μm cell strainers. Next,
the suspended cells were centrifuged at 1500 rpm for
10 min. After removing the supernatant, erythrocyte lysis
buffer (Solarbio) was used to resuspend the cell pellets and
incubated on ice for 5 min. The cell pellets were washed
twice with 1 × PBS.
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2.3 Tissue microarrays and multiplex
quantitative immunofluorescence
A total of 235 formalin-fixed paraffin-embedded liver can-
cer samples were collected randomly fromHCC patients at
Zhongshan Hospital, Fudan University (Shanghai, China)
during 2006 and 2007. As mentioned previously, tissue
microarrays (TMAs) were conducted by Shanghai Biochip
Co., Ltd. It was carried out according to the instruction
by the multiplex quantitative immunofluorescence stain-
ing for TMAs slides. Slides were fluorescently stained
with CD8, PD1, CD4, and FOXP3 antibodies by Opal
7-Color Manual IHC Kit (NEL811001KT), and the Vec-
tra Polaris multispectral imaging system (PerkinElmer)
was used to acquire multispectral images of arrays. As
reported before,26 aftermultilabeled immunofluorescence,
cells were identified through the Cell Segmentation func-
tion of Inform software. Then Score function was used
to calculate fluorescence intensity. A positive rate of
cells refers to the fluorescence intensity of a single-cell
exceeded the threshold value. Positive rates of makers
(such as CD8+, CD8+PD-1+) in peritumor or tumor were
divided into low and high expression groups according to
a cutoff value of overall survival (OS) assessed by X-tile
3.5.0.
2.4 FACS analysis
Cells were stained with CD4 (BioLegend, clone: RPA-
T4), CD3 (BioLegend, clone: HIT3a), CD8 (BioLegend,
clone: SK1), PD-1(Biolegend, clone:EH12.2H7), CD45RO
(Biolegend, clone:UCHL1), CD45RA(BD Pharmingen,
clone:HI100), T-bet (BioLegend, clone: 4B10), Eomes
(R&D, 644730), Blimp(BD, cline: 6D3), NFATC (Biole-
gend, clone: 7A6), PFR (Biolegend, clone: dG9), CD16
(BD Pharmingen,clone: B73.1), CD56 (BD Pharmingen,
clone: MY31), CD25 (BD Pharmingen, clone: 2A3),
CD127 (BD Pharmingen, clone: HIL-7R-M21), IFN-γ
(BD Pharmingen, clone: B27) conjugated to various
fluorochromes. FACS analysis was conducted on a BD
FACS Aria II flow cytometer, and FlowJo v10 was used for
analysis.
2.5 Single-cell RNA sequencing
CD3+ cells from blood and tissues were sorted by using
the Human CD3 Microbeads Isolation Kit (Miltenyi
Biotec, 130-050-101). Immune response of isolated cells
was analyzed at the single-cell level by the BD Rhap-
sody Single-Cell Analysis System and BD Rhapsody™
Immune Response Panel (Human). A total of 6267 cells
were sequenced (Table S1 in the Supporting Information).
The amplification system and the library of the single-cell
mRNA transcriptome final sequencing were obtained by
targeted amplification. The analysis process was started
with the FASTQ files of paired between Read1 and Read2,
and through multistep quality inspection filtering, sample
marker retrieval, single-cell expression profile matrix gen-
eration, single-cell population cluster analysis, and finally
was completed by single-cell targeted sequencing. Every
cell was detected 399 target genes associated with T cell
function.
2.6 ATAC-seq sample preparation,
sequencing, and analysis
CD3+CD8+CD45RO+ cells were isolated from tumor or
adjacent tissue of HCC patients by FACS (Aria II from
BD). As mentioned previously,27 the ATAC-seq libraries
were prepared using 50,000 cells from each sample. In
brief, cells were suspended in 50 μL lysis buffer (0.1%
(v/v) IGEPAL R© CA-630, 10 mM Tris–HCl (Ph 7.4), 3 mM
MgCl2, 10 mM NaCl), and washed with ice-cold PBS.
The nuclei pellets were incubated in 50 μL tagmenta-
tion mix: 2× reaction buffer and 2.5 μL Tn5 Transposase
(Nextera kit, illumina) at 37◦C for 30 min. The Qiagen
MinElute PCR purification kit was used to purify this
labeled DNA, and the ATAC-seq libraries were prepared
by the NEBNext Ultra DNA kit, and sequenced with illu-
mina Hiseq2000 using 75 bp paired-end reads after size
selection.
Reads were trimmed andmapped into items of the refer-
ence human genome (UCSC hg38) using Bowtie 2, then fil-
tered on quality, removing duplicates and reads mapped to
the M chromosome using SAM tools and Picard tools. For
downstream analysis, we normalized the reading counts
to 1× depth (reads per genome coverage, RPGC) by the
“bamCoverage” function of deep Tools.28 The peak calling
was conducted by “callpeak” function of MACS2 with the
following parameters: –nomodel –shift -100 –extsize 200
–q 0.05. The signal tracks were visualized by the UCSC
genome browser.
2.7 Statistical analysis of in vitro tests
Statistical analysis was conducted with prism 5 software
(Graph pad). Paired or unpaired two-tailed Student’s t tests
were carried out on comparisons of two groups. Contin-
gency table analysis and χ2 tests were utilized to exam-
ine the relationship between clinical data and multil-
abeled immunofluorescence data of TMAs. As reported
before,26 we calculated positivity of CD8+, CD8+PD-1+
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cells in duplicate for each dot. Then, the OS cutpoint was
judged according to X-tile 3.5.0, and the positivity of CD8+,
CD8+PD-1+ cells from tumor or normal tissues. TMA was
divided into low or high expression group. The chi-square
test was used for statistical analysis, and statistically sig-
nificant was defined P values of < .05. So as to research on
survival or recurrence rates, Kaplan-Meier estimates were
used to calculate and plot time to recurrence (TTR) curves
andOSwithGraphPadPrism5. The basis for TTRgrouping
and the aforementioned OS statistics were the same. All
data of life tables were analyzed using the statistical pack-
age SPSS to investigate 1-, 3-, and 5-year OS and recurrence
rates. COX regression analysis was conducted for univari-
ate and multivariate analysis of hazard ratio using SPSS
statistics.
3 RESULTS
3.1 Clinical information and clinical
relevance of Tex in HCC
We collected 235 HCC patients’ tissue array and summa-
rized their clinical information in Table 1. All patients have
more than 5 years of follow-up. Through univariate and
multivariate analysis, 15 key clinicopathological features
were calculated to evaluate their relevance of the time to
relapse (TTR) and the OS in HCC. The infiltrating Tex pre-
sented in the tumor core (TM) or ANTs were determined
by multiplex quantitative immunofluorescence staining of
PD-1, CD8, and DAPI.
Double positive of PD1 and CD8 markers was used to
define the exhaustion status. More Tex and Treg accumu-
lated in tumor (Figure 1A, B; Supplemental Figure 1a and
1b). We divided all samples into low or high group accord-
ing to their PD1 expression. Then the association between
the PD1 expression of CD8+T cells and 15 clinical measure-
mentswas analyzed. The data of Table 1 showed that in per-
itumor tissue, positive HBsAg infection significantly cor-
related with higher PD1 expression (P = .026). Combing
peritumor and tumor staining together, advanced tumor
stage (Edmondson-Steiner) predicts enhanced PD1 expres-
sion in CD8+T cells (P = .018, data not shown). Then we
found the location of Tex is significant clinically relevant in
HCC. Fewer Tex in peritumor predicts higher survival rates
of patients and lower recurrence (Figure 1C). Meanwhile,
in tumor, fewer Tex predicts increased recurrence probabil-
ity (Figure 1C). Taken together, the data suggest that first
the accumulation of Tex is tightly related with clinical out-
come of HCC and second the location of Tex has different
prediction values.
3.2 ScRNA and clustering analysis
The clinical characteristics highlight critical and predictive
values of peritumor or tumor Tex; it suggests the impor-
tance of exploring the diversity of immune cells in HCC.
Therefore, we performed deep scRNA on CD3+ cells iso-
lated from tumors, adjacent normal tissues, and periph-
eral blood from HCC patients. The process is shown in
Figure 2A. A total of 6267 cells from two patients (no. 21
and no. 22) was sequenced to detect lower expressed tran-
scription factors and cytokines. The list of immune genes
detected in the study is provided in Table S1 in the Support-
ing Information.
To illustrate the unique construction and underlying
functional subgroups of the entire CD3+ cell population,
unsupervised clustering of total CD3+ cells were car-
ried out by the spectral clustering method. Altogether,
we identified 10 stable cell clusters, including exhausted
T cells, natural killer cells (NKs), gamma delta T, Treg
cells, effector CD8+T cells, effector CD4+T cells, naïve T
cells, monocyte and dendritic cells (DCs), granulocytes,
etc. Since the proportion of monocyte and DCs, granu-
locytes were negligible due to CD3+ beads sorting, we
excluded them in the further analysis. Exhausted CD8+T
cells were dominant in tumor tissues and accounted for
29.25% and 24.58% of CD3+ cells (Figure 2B). At the same
time, Treg cells accounted for 27.41% and 10.06% of CD3+
cells in tumor tissues, higher than ANT and blood (Fig-
ure 2B). Meanwhile, NKT, effector CD8+ or CD4+T cells
predominantly existed in blood and peritumor tissues,
respectively (Figure 2B). The distribution of clusters in the
cell pool is shown in Figure 2C. Also we compared the
aggregation of cells from different origins (blood, peritu-
mor, and tumor; Figure 2D). The data indicated that the
aggregation was shifted between patients (Figure 2D). For
patient no. 21, cells from blood, peritumor, or tumor were
clearly separated. However, for patient no. 23, the bor-
derline was blurred, which suggested the obvious hetero-
geneity between HCC patients. To verify these clusters, we
exhibited representative FACS plots of Naïve T, NKT, Treg,
CD4+Teff, CD8+ Teff, and CD8+ Tex in Supplemental Fig-
ures 2 and 3.
The representative markers in each cluster are shown
in Figure 3. The first cluster is exhausted T cells, except
PDCD1 (not shown), also expressing upregulated exhaus-
tionmarkers such as TIM3, LAG3, andCTLA4 (Figure 3A).
The second cluster, natural killer T cells (NKT), high
expresses characteristic genes such as GNLY, CD16, and
GZMB (Figure 3B), demonstrating their natural killing
activity and effector functions. The third cluster is Tregs
(Figure 3C), which play a role in suppressing immunity in
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TABLE 1 Clinical information of patients
Number of patients Number of patients
Variable CD8+PD-1_Plow CD8+PD-1_Phigh P value CD8+PD-1_Tlow CD8+PD-1_Thigh P value
Age
≤50 yr 71 24 .66 21 74 .321
> 50 yr 101 39 39 101
Sex
Female 30 11 .997 14 27 .164
male 142 52 46 148
HBsAg
Negative 31 4 .026 7 28 .416
Positive 141 59 53 147
TB
≤17 μmol/L 116 50 .075 38 128 .15
> 17 μmol/L 56 13 22 47
ALT
≤70 U/L 148 48 .072 49 147 .675
> 70 U/L 24 15 11 28
ALB
≤3.5 g/dl 9 1 .22 3 7 .741
> 3.5 g/dl 163 62 57 168
Preoperative AFP
≤20 ng/mL 60 23 .818 23 60 .571
> 20 ng/mL 112 40 37 115
Liver cirrhosis
No 25 15 .094 8 32 .378
Yes 147 48 52 143
Tumor size
≤5 cm 107 39 .966 41 105 .251
> 5 cm 65 24 19 70
Multinodular tumor
Single 144 53 .94 53 144 .272
Multiple 28 10 7 31
Edmondson-Steiner
I-II 131 46 .62 46 131 .779
III-IV 41 17 14 44
γ-GT
≤54 92 36 .618 39 89 .058
>54 80 27 21 86
BCLC stage
A 97 38 0.59 38 97 0.285
B+C 75 25 22 78
Vascular invasion
Absent 110 45 .284 38 117 .619
Present 62 18 22 58
Tumor encapsulation
Complete 91 34 .885 33 92 .745
None 81 29 27 83
A I-value < .05 was considered statistically significant. P-values were calculated using the Pearson chi-square test.
Abbreviations: AFP, α-fetoprotein; ALB, albumin; ALT, Alanine aminotransferase; BCLC stage, Barcelona clinic liver cancer stage; γ-GT, γ-glutamyl; HBsAg,
hepatitis B surface antigen; TB, total bilirubin.
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F IGURE 1 Clinical relevance of Tex in HCC. (A) Opal multicolor IHC staining with anti-CD8, anti-PD-1, antibodies, and DAPI. We
developed tissue array of 235 HCC patients and summarized clinical characteristics in Table 1. Each patient has more than 5-year follow-up. (B)
Comparison of CD8+PD-1+ T cells in tumor or peritumor. (C) Clinical relevance of Tex in HCC. TTR and OS curves were plotted in GraphPad
Prism . The horizontal axis showed time after surgery and the vertical axis showed probability of recurrence or OS rates by the corresponding
time. Two sets of data (low vs high) were represented by black and red curve, respectively.low, low expression of indicated biomarkers;high,
high expression of indicated biomarkers. TTR, time to recurrence; DAPI: 4′,6-diamidino-2-phenylindole; HCC: hepatocellular carcinoma; OS:
overall survival; PD-1: programmed death-1; *P < .5; **P < .01; ***P < .001
tumor immunity. It is significantly higher in tumor tissues
than in ANT and PBMC, expressing FOXP3, CD25, ICOS,
and so on. The fourth cluster, cytotoxic CD8+ T cells (Fig-
ure 3D), was significantly decreased in tumors, whichwere
confirmed by gene expressions includingCCL4, IFNG, and
KLRC3. Figures 3E-H exhibited clusters (effector CD4+
cells, resting Treg, gamma delta T cells, naive T cells) and
their expressions of representative markers.
3.3 Transitional exhausted CD8+ T cells
The results above illustrated that suppressive Tregs
and Tex were preferentially enriched in tumor tissues.
Compared with other T cells, we identified a total of 65
genes (adjusted P value < .05, and fold change > 2) that
were specifically expressed in tumor Tex cells, including
PI3, MKI67, UBE2C, TOP2A, IGLC3, TYMS, HMMR,
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F IGURE 2 Single CD3+ cell transcriptome analysis. (A-B), Scheme of the overall study design. Single-cell RNA sequencing was applied to
T cells derived from two patients’ (no. 21 and no. 22) peripheral blood (B), tumor (T), and adjacent normal tissues (P). Paired peritumor tissue or
peripheral blood were obtained from same patients. The adjacent normal tissues were at least 3 cm from the matched tumor tissues. Histogram
showing the average percentage of different types of T cells in different tissues. This table quantified the proportion. (C) T-SNE visualization of
T cells clusters based on 6267 single-cell transcriptomes. (D) The t-SNE projection of two patients, showing the formation of cell origin
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F IGURE 3 T-SNE maps displaying representative markers in each cluster. (A-H) t-SNE maps displaying four representative markers in
each cluster. The clusters include exhausted CD8+ T cell (exhausted CD8), natural killer cell (NK), gamma delta T, Treg cell, effector CD8+T
cell, effector CD4+T cell, and naïve T cell
KIAA0101, CD38, CHI3L2, etc. The top-ranked genes
were multiple known exhaustion markers, such as LAG3,
HAVCR2, and PDCD1. Notably, some genes related to
exhaustion were also overexpressed in tumor-infiltrating
Tregs including TYMS, KIAA0101, CXCL13, CD27,
HLA-DQB1, HLA-DMA, ENTPD1, CD200, DUSP4, and
ZBED2.
The two CD8+T cell clusters (CD8-CTLA4, CD8-IFNG)
have distinct distributions, respectively, representing
Tex and effector CD8+T cells. Exhausted CD8+T cells
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were found to be enriched in tumor, whereas effector
CD8+T cells were the major group located in peritumor
(Figure 2B). Tex specifically overexpressed multiple coin-
hibitory factors such as CTLA4 and ICOS (Figure 4A).
We exhibited top well-recognized exhaustion genes in
Figure 4A. Also we analyzed the PD1 staining in a tissue
microarray of 235 HCC patients as shown in Figure 1A.
The data showed that CD8+PD1+T cells significantly accu-
mulated in tumor than them in peritumor (Figure 1B).
Next, we believe these genes that were uniquely regulated
in T cells also exhibited specific epigenetic changes, which
would providemore robust and stable signature of exhaus-
tion. To verify this hypothesis, we identified enhancers in
exhausted CD8+T cells fromHCC by epigenomic profiling
by assay for transposase-accessible chromatin with high
throughput sequencing (ATAC-seq). Over 4662
differentially accessible genes based on the peak
annotation were identified in ATAC-seq data of sorted
CD3+CD8+CD45RO+ T cells between peritumor and
tumor, showing substantial chromatin remodeling. For
example, TIGIT, CTLA4 had more accessible open chro-
matin regions (OCRs) in tumors (Figure 4B). Therefore,
some differentially expressed exhaustion-specific genes,
as identified in our scRNA analysis, were also associated
with epigenetic changes.
We next sought to explore the expression of genes encod-
ing key transcription factors (TFs) that enable T cell devel-
opment. The heatmap revealed different TFs expression
patterns across these clusters (Figure 4C). Tex and effector
CD8+T cells shared similar TFs, but Tex expressed more
TCF4. In comparison to naïve T cells or resting Tregs, sup-
pressive Tregs (CD4-FOXP4) exhibited distinct TFs expres-
sions. We then examined the protein level of these TFs
and found that Eomes was in fact differentially expressed
in CD3+CD8+CD45RO+T cells from tumor and peritu-
mor (Figure 4D, P < .05), with increased expression in the
tumor.
Enhanced Eomes expression may imply that tumor had
an “advanced exhaustion” phenotype, where cytokine pro-
duction is impaired, and poor proliferative potential is
observed despite partial cytotoxicity ability.29 However, we
found both CD8 clusters expressed high levels of effector
genes including GZMA and GZMK (Figure 5), therefore
representing their effector CD8+T characters. However,
cell cycle, growth factor-related genes were upregulated in
Tex. In contrast, stress response was downregulated in Tex.
The difference indicates that CD8+ T cell exhaustion sug-
gests the specific status of gene expression compared with
that of naive, effector CD8+ T cells. The “CD8-CTLA4” is
a cluster of CD8+T cells during the transitional state from
activation to exhaustion at an early stage, as seen by main-
taining effector functions although some exhaustion genes
were expressed (Figure 5).
3.4 Transitional regulatory CD4+T cells
CD4-FOXP3 (suppressive Tregs) and FOXP3-LEF1 (rest-
ing Tregs, rTregs) shared Treg signature genes (FOXP3,
CD4). RTregswere CD45RA+Foxp3loCD4+; suppressive or
activated Tregs were CD45RA−Foxp3highCD4+.30,31 They
were present with location preferences. Suppressive Tregs
were accumulated in tumor, but FOXP3-LEF1 T cells were
evenly distributed in peritumor, tumor, and blood (Fig-
ure 2B). The increased population of suppressive Tregs
in tumor and the widespread expression of coinhibitory
receptors (Figure 2B) potentially supported the immune-
suppressive nature of the tumor microenvironment.
RTregs, when stimulated, can increase Foxp3 expres-
sion, convert to suppressive Tregs, and proliferate.8,31
In Figure 6, the differentiation pattern of suppressive
Treg cells was significantly changed compared with
rTreg, including a distinct expression pattern of TFs,
chemokines, chemokine receptors, cytokines, and inter-
leukins (Figures 5 and 6). This reflects heterogeneity and
gradual development of regulatory T cell development.
The altered pathways identified in resting Treg or suppres-
sive Tregs suggested potential targets for of therapeutic
intervention in HCC.
4 DISCUSSION
Exhausted CD8+T cells and Tregs significantly
affect tumor progress and efficiency of cancer
immunotherapy.32,33 Here, we investigated immunity
in HCC patients with emphasis on the profiling of T cell
subjects through deep single-cell targeted immune profil-
ing on CD3+ cells. We discovered for the first time that
there are 10 clusters with distinct distributions and char-
acteristics in HCC. We observed increased accumulation
of Tex and Tregs in tumors. We further discussed changes
related to the differentiation of Tex and Tregs. Under-
standing the altered pathways will help in designing new
strategy for intervening progressive immunosuppressive
microenvironment in HCC.
Exhausted T cells could be reinvigorated by the blockade
of PD-1, other inhibitory receptors, or immunoregulatory
pathways.14,34,35 As we reported before, exhaustion is a
progressive process in which cells over time express one
or multiple inhibitory receptors. Multiple markers (LAG3,
TIM3, CTLA4, PD1, etc.) were coexpressed in exhausted
T cells of HCC. These therapies assume that exhausted T
cells might be reversed, or these cells are not terminally
exhausted and can contribute to protective immunity
if reinvigorated.36 In the study, interestingly, we found
that the location of Tex accumulation is differentially
related to clinical outcome of HCC patients. Fewer Tex
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F IGURE 4 Characteristic of exhausted CD8+ T cells. (A) Dot plots showed the gene expression frequency made with BD’s data view
software. (B) The exhibition of accessible OCRs based on peak annotation with high throughput sequencing (ATAC-seq) data of sorted
CD3+CD8+CD45RO+ T cells between peritumor and tumor. Paired peritumor tissue and tumor tissue were obtained from same patients. The
adjacent normal tissues were at least 3 cm from the matched tumor tissues. (C) Different transcription factors (TFs) expression patterns across
different clusters. (D) The expression of these TFs at the protein level in CD3+CD8+CD45RO+T cells from tumor and peritumor by flow cytom-
etry. The sample were obtained as described in Figure 4B
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F IGURE 5 Comparison of key features between clusters. Heat map showing normalized mean expression of selected T cell function-
associated genes from scRNA in each cell cluster. It included critical genes coding effector molecule, NK cell receptor, MHC class I and II, cell
cycle growth factor complement protein and stress response
in normal tissues estimates higher survival rates and
lower recurrence of patients. (Figure 1C). In contrast, in
tumor, fewer Tex predicts increased recurrence probability
(Figure 1C). The data suggest that heterogeneity of Tex
between intratumor or peritumor. The different functions
and states of Tex determine the distinct clinical relevance.
Therefore, defining the heterogeneity and abundance
of early or terminal exhausted T cells becomes extremely
important as a predictor of the check-point blockade treat-
ment. From scRNAdata,we observed transitional differen-
tiation of Tex were increasingly enriched in intratumor tis-
sue. We found that the specific cluster Eomes+ cluster that
was considered as a phenotype of terminal CD8 exhaus-
tion subset showed diminished effector function.37,38 How-
ever, genes that indicate effector functions, such as IFNG,
GZMK, and GZMA, were retained in this subset (Fig-
ure 5). Therefore, we think Eomes is not reliable marker
for the terminal exhaustion. Because the distinct tumor
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F IGURE 6 Heat map of differentially expressed genes coding chemokines, chemokine receptors, cytokines, and interleukins in each
cluster. GraphPadPrism 5was used to generate the heatmap for exhibiting normalizedmean expression of these genes from twopatients’ scRNA
microenvironments are likely to influence T cell biology,
we proposed that the definition of exhausted T cell is
high variable in different diseases or locations. On the
other hand, ATAC-seq revealed some immune cosuppres-
sor molecules in tumor T cells and displayed a more
opened chromatin structure, suggesting potential regula-
tions of exhausted T cell formation as reported before.32,39
In Figure 5, cells displayed altered gene expression
related to cell cycle and stress response at early exhaus-
tion stage. Activated T cells included cytotoxic T cells and
helper T cells, which mediated cellular immune responses
by upregulating stress response genes as shown in Figure 5.
Interestingly, signal transduction of cell death (EGR3,
EGR1, JUN, DUSP1, JUNB, IER3) especially regulating
early growth responses is suppressed in exhausted CD8+T
cells. Thus, functional exhaustion is probably caused by
the combination effects of passive defects and overactiva-
tion in stress response. Therefore, T cell exhaustion was
a progressive process, and the gene expression profiles
demonstrated T cell exhaustion and anergy are distinct.
Treg cells, a specialized lineage of suppressive CD4+
T cells, play a vital role in immune-tolerance in various
biological contexts.40 Treg cells exposed to inflamma-
tory or tumor conditions obtain strongly enhanced
suppressive function.41 Effector CD4+, resting Treg, and
suppressive Treg cells are transcriptionally different
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(Figure 4C); Tumor-infiltrating Treg cells have many
activation-induced changes including upregulated expres-
sion of chemokines, chemokine receptors, cytokines,
and interleukins (Figure 6). We observed interleukin-
10 (IL-10) signaling pathway (CSF2, CXCL10, IL1RN,
ILR2, CCL22) is overactivated in suppressive Treg. IL-
10 is an anti-inflammatory cytokine with important
immunoregulatory functions.42 It is a cytokine with
effective anti-inflammatory properties, repressing Th17
cell-mediated inflammation, and inflammatory cytokines
production such as TNF-α and IL-6.43 Immunosuppressive
Tregs have profound activation in comparison to resting
Treg.
In summary, our study highlights transitional states
of T cells associated with HCC. The results indicate the
essential significance of immune status assessment in
the context of tumor biology context. Current studies
about the mechanisms of T cell exhaustion have pro-
vided some new perspectives as well as clinical directions
and opportunities.44 In spite of the current progress, our
research remains incomplete on the mechanism of T cell
exhaustion and how to reverse this state more effectively.
This study has several limitations. First of all, in the work-
flow of scRNA analysis, clustering is crucial for draw-
ing conclusions. For cell type annotation, errors would be
introduced into this process by the lack of specific mark-
ers or inadequate clustering analysis. In the study, we used
combined analysis of bioinformatics methods and biolog-
ical knowledge. Although some genes were expressed in
different types of cells, the expression levels were differ-
ent. We determined the cell type by the expression of most
significant differentially expressed genes in each cluster.
Second, we need collect more samples to depict the het-
erogeneity of HCC immune microenvironment. Mean-
while, further functional experiments are required to ver-
ify the relationship between cell dynamic differentiation
and function in the tumor microenvironment, as well
as the relationship between differentiation of T cell and
tumor progression, so as to find targets for tumor interven-
tion. Further clinical researches and mechanistic studies
are necessary to develop the next generation of immune-
based interventions against cancers and chronic infections.
The study shows the dynamic framework of T cells func-
tion in cancer, especially for designing rational cancer
immunotherapies.
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